Ibrexafungerp  (Synonyms: MK 3118; SCY-078)

Ibrexafungerp (MK 3118) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp can be used for research of Candida and Aspergillus infections^[1].

brexafunerp 对多种念珠菌 (Candida) 属具有抗真菌活性，MIC 为 0.5 µg/mL^[2]。
Ibrexafungerp 有效对抗 C. albicans, C. krusei, C. parapsilosis 感染，MIC 为 0.06、0.5、0.25 µg/mL^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ibrexafunerp (口服，10 mg/kg) 可有效抵抗豚鼠皮肤梭状芽孢杆菌 (C. auris) 感染^[4]。
Ibrexafungerp (口服，小鼠 1 mg/kg，大鼠 5 mg/kg 和狗 5 mg/kg) 表现出口服生物利用度 (小鼠 51%，大鼠 45%，狗 35%)^[3]。
Ibrexafungerp (尾静脉注射，小鼠 1 mg/kg，大鼠 5 mg/kg 和狗 5 mg/kg) 表现出血浆清除率高，半衰期适中 (小鼠 5.5、大鼠 8.7 和狗 9.3 小时)^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

730.03

C₄₄H₆₇N₅O₄

1207753-03-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. James M Apgar, et al. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021 Jan 15;32:127661.  [Content Brief]

  [2]. Mahmoud Ghannoum, et al. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics (Basel). 2020 Aug 25;9(9):539.  [Content Brief]

  [3]. Stephen A Wring, et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02068-16.  [Content Brief]

  [4]. Ghannoum M, et al. Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00854-20.  [Content Brief]

  [5]. Arendrup MC, et al. In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02136-19.  [Content Brief]